+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incidence and risk factors of EBV related post transplant lymphoproliferative diseases in paediatric liver transplant recipients treated with tacrolimus



Incidence and risk factors of EBV related post transplant lymphoproliferative diseases in paediatric liver transplant recipients treated with tacrolimus



Hepatology 26(4 Part 2): 343A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 031876821

Download citation: RISBibTeXText


Related references

Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 64(10): 1438-1442, 1997

Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatric Transplantation 5(5): 359-364, 2001

Incidence and risk factors for post-transplant lymphoproliferative disorder among renal transplant recipients. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 564A, 2002

Incidence of post-transplant lymphoproliferative disease among organ transplant recipients under tacrolimus immunosuppression. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35: 204, 1995

Minimal toxicity and low incidence of post transplant lymphoproliferative disease with tacrolimus-based immunosupression in pediatric transplant recipients. JPGN 31(Suppl. 2): S267, 2000

Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort. Transplant Infectious Disease 20(1):, 2018

The use of objective case ascertainment to identify risk factors for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder in pediatric liver transplant recipients. Hepatology 36(4 Part 2): 662A, 2002

The incidence of Post-Transplant Lymphoproliferative Disorder in children and adults under tacrolimus 2,000 Consecutive liver transplant patients. Hepatology 36(4 Part 2): 662A, 2002

Epstein-barr virus-related post-transplant lymphoproliferative disorder in a renal transplant recipient treated with tacrolimus and antithymocyte globulin. Clinical Drug Investigation 23(4): 281-283, 2003

Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clinical Transplantation 20(3): 389-393, 2006

Risk factors for post transplant lymphoproliferative disorder ptld in renal transplant recipients. Journal of the American Society of Nephrology 2(3): 795, 1991

Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. American Journal of Transplantation 5(3): 566-572, 2005

Analysis of risk factors for post-transplant lymphoproliferative disease in pediatric lung transplant recipients with cystic fibrosis. Pediatric Research 43(4 Part 2): 131A, 1998

Risk factors that influence survival in kidney transplant recipients with post-transplant lymphoproliferative disease A multivariate analysis. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 178A, 2002

Epstein-Barr virus-related post transplant lymphoproliferative disease of donor origin in two orthotopic liver transplant recipients. Hepatology 22(4 Part 2): 210A, 1995